BSX Overview

Key Data

  • Open $43.87
  • Day Range 43.68 - 44.08
  • 52 Week Range 32.99 - 44.63
  • Market Cap $62.69B
  • Shares Outstanding 1.42B
  • Public Float 1.42B
  • Beta 1.05
  • Rev. per Employee $260.87K
  • P/E Ratio 449.59
  • EPS $0.10
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 12.35M 07/15/21
  • % of Float Shorted 0.87%
  • Average Volume 6.58M

Performance

5 Day
  • 2.76%
1 Month
  • 1.71%
3 Month
  • 3.68%
YTD
  • 22.31%
1 Year
  • 14.89%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Boston Scientific Raises Full-Year Adj Earnings Guidance Range

Boston Scientific beats earnings expectations and boosts full-year outlook

Boston Scientific 2Q Sales Recover

Boston Scientific sees Q3 sales up 12% to 14%

Boston Scientific now sees full-year sales up 21% to 22%

Boston Scientific Q2 sales $3.077 bln vs. $2.003 bln a year ago; FactSet consensus $2.940 bln

Boston Scientific Q2 adj. EPS 40 cents; FactSet consensus 37 cents

Boston Scientific Q2 EPS 12 cents vs. loss per share 11 cents a year ago

Boston Scientific Corp. stock outperforms competitors despite losses on the day

Boston Scientific Corp. stock outperforms competitors on strong trading day

Boston Scientific Corp. stock underperforms Thursday when compared to competitors

Boston Scientific Corp. stock outperforms competitors on strong trading day

Boston Scientific Corp. stock outperforms competitors on strong trading day

Boston Scientific Corp. stock falls Monday, underperforms market

Boston Scientific Corp. stock falls Friday, still outperforms market

Boston Scientific Corp. stock falls Thursday, underperforms market

Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Boston Scientific Corp. stock underperforms Tuesday when compared to competitors

Boston Scientific Corp. stock falls Monday, underperforms market

Boston Scientific Corp. stock rises Friday, still underperforms market

  • Other News
  • Press Releases

Boston Scientific’s WATCHMAN Could be a Potential Winner, Despite Headwinds

on TipRanks.com

Boston Scientific to Acquire Remaining Stake in Farapulse for $295M

on TipRanks.com

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Encompass Health (EHC) and Prothena (PRTA)

on SmarterAnalyst

Better Buy: Medtronic or Boston Scientific?

on Motley Fool

Wednesday’s Top Analyst Upgrades and Downgrades: AMD, Boston Scientific, Intel, Kinder Morgan, Riot Blockchain, Virgin Galactic and More

on 247WallSt.com

Needham Downgrades Boston Scientific (BSX) to Hold

on SmarterAnalyst

Boston Scientific, Gap, Molson Coors and More Tuesday Afternoon Analyst Calls

on 247WallSt.com

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Hologic (HOLX)

on SmarterAnalyst

Wall Street Analysts Are Bullish on Top Healthcare Picks

on SmarterAnalyst

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and Apellis Pharmaceuticals (APLS)

on SmarterAnalyst

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Exelixis (EXEL) and Flexion Therapeutics (FLXN)

on SmarterAnalyst

Boston Scientific (BSX) Receives a Buy from Needham

on SmarterAnalyst

Boston Scientific Corp (BSX) Q1 2021 Earnings Call Transcript

on Motley Fool

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Oncternal Therapeutics (ONCT) and Integra Lifesciences (IART)

on SmarterAnalyst

AMD, Boston Scientific, Intel, Nvidia and More Thursday Afternoon Analyst Calls

on 247WallSt.com

Medtronic Is Healing Hearts and Padding Portfolios

on Motley Fool

1 Healthcare ETF Proven To Strengthen Your Portfolio

on Motley Fool

1 Healthcare ETF Proven to Strengthen Your Portfolio

on Motley Fool

If I Had $5,000, This Is How I'd Invest It

on Motley Fool

The 7 Best Startups You Can Buy on StartEngine Right Now

on InvestorPlace.com

Boston Scientific Corp.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Competitors

Name Chg % Market Cap
Abbott Laboratories -1.06% $214.64B
Medtronic PLC -0.37% $172.75B
Stryker Corp. 0.33% $98.96B
Becton Dickinson & Co. -0.66% $73.02B
Edwards Lifesciences Corp. -0.47% $68.01B
Baxter International Inc. -0.46% $40.8B
Zimmer Biomet Holdings Inc. -0.20% $33.35B
Teleflex Inc. -0.06% $18.6B
Abiomed Inc. -1.07% $14.9B
Becton Dickinson & Co. Dep. Pfd. (Rep. 1/20th Pfd. Series B) -0.02%
Competitor Data Provided ByCapital Cube Logo